This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Quest Diagnostics To Acquire Clinical Outreach Laboratory From UMass Memorial Medical Center; Plan To Build 'Lab Of The Future' To Serve Massachusetts Health Care Community

In the news release, Quest Diagnostics to Acquire Clinical Outreach Laboratory from UMass Memorial Medical Center; Plan to Build 'Lab of the Future' to Serve Massachusetts Health Care Community, issued 16-Oct-2012 by Quest Diagnostics over PR Newswire, we are advised by the company that the seventh paragraph, second sentence, should read "be neutral to earnings per share in 2013, and accretive to earnings per share in 2014," rather than "be neutral to earnings per share in 2012, and accretive to earnings per share in 2013" as originally issued inadvertently. The complete, corrected release follows:

Quest Diagnostics to Acquire Clinical Outreach Laboratory from UMass Memorial Medical Center; Plan to Build 'Lab of the Future' to Serve Massachusetts Health Care Community

--Relationship will provide innovation, resources, and expanded access and connectivity for patients and doctors' offices, all at reduced costs--

MADISON, N.J. and WORCESTER, Mass., Oct. 16, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world leader in diagnostic testing, information and services, signed a definitive agreement today to purchase the clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care and the largest health care system in Central New England.

The sale is the first step toward establishing a long-term relationship between the two organizations that could result in UMass Memorial taking a financial stake in a new entity that would develop and operate a state-of-the-art laboratory in Massachusetts in the future. The relationship will result in a number of benefits for patients, physicians, hospitals and health plans, including even higher quality service, expanded information connectivity options, and reduced laboratory testing costs. 

Quest Diagnostics' full-service laboratory in Cambridge, Mass., and its Athena Diagnostics specialty neurology testing subsidiary in Worcester, Mass., will move to a new facility that is expected to be centrally located in the area. This facility, when fully operational, will perform the testing currently performed at UMass Memorial's Worcester-based outreach laboratories, the Quest Diagnostics testing currently performed in Cambridge and the testing performed by Athena. It is expected that the full transition of services will take place over the next 18 to 24 months, with details to be announced as they are finalized.

In addition, the two organizations view this combination of resources as the opportunity to work together in the future on many different fronts to provide physicians, patients and the healthcare community with the highest quality diagnostic testing through the lowest cost delivery model.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs